DxS appoints Ron Long as Chairman as part of Continued Growth and Expansion Strategy

Manchester, 9th June 2009 DxS Ltd, a personalised medicine company and leaders in the provision of companion diagnostics, has today announced the appointment of Ron Long as the company Chairman.

Ron has a wealth of experience in both public and private companies stretching over 40 years, with an impressive record of leadership in a number of companies, including the Wellcome Foundation, and Amersham Plc where he was Vice Chairman.

Ron has served as non-executive director of DxS since July 2008 and replaces David Evans as Chairman who steps down. Ron retains his positions at Medivir AB and Procognia Israel Ltd.

Commenting on Ron’s appointment, Dr Stephen Little, CEO of DxS said “Ron’s depth and breadth of experience in the field of personalised medicine will be crucial as DxS continues to expand. Having secured a number of important deals with some of the biggest names in the life sciences area, and with increasing interest in our products, DxS is now in a very strong position to build on these foundations.

“I would also like to take this opportunity to thank former Chairman David Evans for his guidance and leadership over the past 3 years. His strategic insight in steering the company’s transformation from a reference genetics laboratory to a thriving molecular diagnostics products company has been crucial to our current success.”

DxS has more than doubled in size in the last twelve months with new manufacturing space taken at their Manchester site as a result of a global distribution deal agreed with Roche Molecular Diagnostics for their TheraScreen® diagnostic kits, and a deal which has seen Amgen and Merck Serono/Bristol Myers Squibb use DxS’ TheraScreen: K-RAS Mutation Kit as a companion diagnostic for the colorectal cancer treatment Vectibix® and Erbitux®.

-ends-

For further information, please contact:

Sue Charles, Tony Stephenson, Dr John McIntyre
College Hill Life Sciences
+44 (0)20 7866 7864
DxS@collegehill.com

Notes to Editors

DxS is a personalised medicine company providing molecular diagnostics to aid doctors and drug companies in selecting therapies for patients. Working in partnership with pharmaceutical companies to support the development and sales of targeted cancer therapies by providing biomarkers and companion diagnostics.

DxS has a continually expanding portfolio of cancer mutation products. The TheraScreen® range of CE-marked clinical diagnostic kits can identify genetic tumour mutations that affect how patients respond to cancer therapies, thus enabling doctors to provide the most beneficial treatment. DxS produce two clinical diagnostic kits, K-RAS and EGFR-29.

The TheraScreen: K-RAS Mutation kit is a companion diagnostic for Vectibix® (Amgen) and Erbitux® (Merck KGaA) for the treatment of colorectal cancer. DxS has an exclusive global distribution agreement with Roche Diagnostics for the distribution of the TheraScreen: K-RAS and TheraScreen: EGFR29 Mutation kits.

DxS’ pioneering real-time PCR technology Scorpions® is highly regarded for its proven speed and sensitivity, and is combined with ARMS (allele specific PCR) to develop each unique DxS product. This class-leading technology is also available for licence to diagnostic companies, for research, or for other varied applications.

DxS is a private, venture capital-backed company operating from the heart of Manchester’s Technology Quarter in the UK.

For further information please visit www.dxsdiagnostics.com.